Why EU Must Reform Regulation And Funding For Life-Saving Cancer Biomarker Tests
Executive Summary
UK and EU patients have inadequate and inconsistent access to cancer biomarker tests, which experts warn is hindering the use of life-saving targeted medicines. Could parallel regulatory and reimbursement processes for drugs and diagnostics provide a solution?
You may also be interested in...
Should Pharma Firms Cover CDx Costs For Precision Cancer Drugs?
Significant financial reward awaits drugmakers that invest more in companion diagnostics during the development and marketing of precision cancer drugs, says Peter Keeling, CEO of Diaceutics – but Novartis warns that relying on pharma firms to fund these tests is unsustainable.
Should Pharma Firms Cover CDx Costs For Precision Cancer Drugs?
Significant financial reward awaits drugmakers that invest more in companion diagnostics during the development and marketing of precision cancer drugs, says Peter Keeling, CEO of Diaceutics – but Novartis warns that relying on pharma firms to fund these tests is unsustainable.
MedTech Europe IVDR Impact Report: The Good, The Bad And The Ugly
The outcome of a survey by trade association MedTech Europe shows that while more than 90% of companies benefited from the extension of IVDR transition deadlines, significant issues remain that could see many diagnostics disappear from the market.